FDA finds mystery ‘deficiencies’ with Neos’ long-acting Ritalin on the eve of approval

Damian Garde

Therapeutics got an ominous note from the FDA just weeks ahead of the expected date for its long-acting ADHD treatment, clouding the future of the company's lead asset.

FierceBiotech News

Share This Post

Related Articles

Leave a Reply

© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS